PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Good EULAR Response In Patients With Early Rheumatoid Arthritis
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT01558089
- Locations
- π¬π·
G. Papanikolaoy, Thessaloniki, Exochi, Greece
π¬π·"Olympion therapeutic center" General Clinic of Patras, Patras, Greece
π¬π·424 Military Hospital, Thessaloniki, Thessalonikis, Greece
An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
- Conditions
- Plaque Psoriasis Patients
- Interventions
- Other: Enbrel treatment
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT01557283
- Locations
- π§πͺ
Herestraat 49, Leuven, Belgium
Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1754
- Registration Number
- NCT01557322
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
- Conditions
- Urinary Bladder, Neurogenic
- Interventions
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 181
- Registration Number
- NCT01557244
- Locations
- π§πͺ
HΓ΄pital Universitaire des Enfants Reine Fabiola, Bruxelles, Bruxelles-capitale, Belgium
π―π΅Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
π―π΅Fukuoka Children's Hospital, Fukuoka-shi, Fukuoka, Japan
Pharmacokinetics Study of ALO-02 and OxyContin
- Conditions
- Management of Moderate to Severe Pain
- Interventions
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT01557257
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01549574
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 255
- Registration Number
- NCT01546038
- Locations
- πΊπΈ
Keck Hospital of USC, Los Angeles, California, United States
πΊπΈUniversity of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
πΊπΈLAC & USC Medical Center, Los Angeles, California, United States
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT01547299
Escape Smoke Project: Non-Intervention Non-Drug Multicenter Study on the Real-life Effectiveness of Smoking Cessation in General Practice in Denmark
- Conditions
- Smoking Cessation
- Interventions
- Other: Smoking cessation
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 544
- Registration Number
- NCT01544621
Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01544673
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States